boyband6666

9 ms·

31.
by boyband6666 7y ago
As well as academic papers, I use it for storing copies (wiut hthe chrome plugin) of websites - things are not permanent these days and may reference sources I wouldn't want to lose! It's basically my personal library
32.
by boyband6666 7y ago
I don't debate these make it better, but it doesn't seem like they should be required - most of the features are pretty standard!
33.
by boyband6666 7y ago
I also found that extraordinary. With such limited information it is not possible to know if the contacts I have are relevant, and how serious and progressed the company are. After all if I suggest something I'm putting my reputation (
34.
by boyband6666 7y ago
I agree here. Also myfitnesspal doesn't let you easily correct things for being wrong; case in point many products list only the calories for something, and not the macros/nutrients. I often search for something as a proxy for wha
35.
by boyband6666 7y ago
If runners world are interested, theres probably some way of contacting me through here (I've now idea on the best way) and I am happy to add in to the story with some concrete details. For me it was a long day at the office and not wh
36.
by boyband6666 7y ago
Sponsoring races might work, semi-major ones who have a magazine and you can suggest it to, but that's going to cost (I've no idea on your funding, and don't need to know). The freeone would be an adverotial type approach in
37.
by boyband6666 7y ago
I forget which app it was, but when in the US for the Boston Marathon this year, my friend and I used one of these systems. It was amazing - we left one set of cards and a phone in a bag the day before, plus clothes. We could then finish th
38.
by boyband6666 7y ago
Your point 2 is very important and what so often gets missed. What is statistically significant may not be clinically significant; throw enough patients at something, especially a surrogate outcome, and you can get p<0.05. The hype hungr
39.
by boyband6666 7y ago
Every job ad I've put up since starting my company has had over 100 candidates. 80 of whom are wholly unsuitable and do not send any cover letter. Another 10 don't bother with the cover letter but may have been suitable. All these
40.
by boyband6666 7y ago
The draft of my (part time) PhD thesis uses draw.io to present a flowchart of the findings - hopefully it makes the final cut next year. Fascinating to hear the other uses, and thankyou for a wonderful and elegant tool!
41.
by boyband6666 7y ago
I'm giving my son a classical education with it. Using Retropi Every now and then we play "Daddy's games", so he has NES megadrive, and MAME (PacMan mainly). As he starts to master those, I'll add the next generatio
42.
by boyband6666 7y ago
If you can find a problem, and solve it, a business is a fantastic way to make an impact!
43.
by boyband6666 7y ago
So as someone working in application of medicines, I'd agree with the comments that say those of us doing these things have learn to make code work, but are not software engineers (and would not claim to be). This means that if you can
44.
by boyband6666 7y ago
... or to accept that the plans were not economically viable as they stand. I'm an economist not a nuclear physicist, but the signal the market is sending is that these plans are not what is needed. Find a way to make the electricity c
45.
by boyband6666 7y ago
Except the strike price used is far above the current market rate, with no real indication that it would reach that level naturally. Describing it as a generous subsidy might not be strictly accurate, but isn't far from the truth. If t
46.
by boyband6666 7y ago
All I can say is if like me you'd bought Energenie MiHomes, you'd have spent half as much working out that you need to think twice becase there are so many bugs that make them not worth using... I seldom hear success stories from
47.
by boyband6666 7y ago
Except for the fact that it's expensive to keep people on HIV meds, thus increasing the value of a cure. And the meds are made by lots of companies in competition - if anyone had science they thought would lead to a cure, they would be
48.
by boyband6666 7y ago
Also the headline is massively misleading - almost immediately they point out that many people don't know their status.
49.
by boyband6666 7y ago
It's been 5 years but I rememeber being in a 2 hour talk (I used to work in vaccines) about the difficulty of coming up with a vaccine for HIV, never mind a cure. It sounded then like it was a long long way off, and we're still on
50.
by boyband6666 7y ago
Collaboration - one control arm, 2+ active drugs from multiple companies (why not 6+?). Fewer patients exposed to placebo, less paperwork, same statistical power, more so if you randomise 2:1:1:1:1:1 rather than a standard trial with 1:1 or
51.
by boyband6666 7y ago
The studies performed are the same ones, but companies submit it to the FDA first, who are more likely to approve, and approve faster than European regulators (the European Medicines Agency, EMA). The FDA are the most permissive regulator i
52.
by boyband6666 7y ago
That's actually a very interesting one, and has been written about at length by a number of medical stats people. Hopefully I do them justice to their arguments by saying that the benefits from supplements (if any) are tiny - as in a h
53.
by boyband6666 7y ago
So I work on the opposite end to discovery, in the interpretation, and estimation of outcomes seen beyond the studies i.e. what impact will the drug have. Applied statistics essentially. The author is completely right about the raw mechanic
54.
by boyband6666 7y ago
Extending patents wouldn't work that well in his model - as you can see from the graphs it is already discounted crazily (I'd argue for a 6% discount rate, not 8, but it hadly changes the calculus). Besides market exclusivity can
55.
by boyband6666 7y ago
I'd also use corporate bonds for pharma companies (or biotechs, depending on which you are looking at) for the cost of capital, as ultimately that's what debt costs
56.
by boyband6666 7y ago
Fully agree - I work with pharma as an independent (and used to work at GSK & Sanofi before that - effectively medical statistics). I'm currently working on a gene therapy from a biotech, if it works it'll be amazing, and be a
57.
by boyband6666 7y ago
The people who say pharma don't want cures generally don't understand the industry. A cure is worth more than a chronic treatment, and the article does an excellent job of explaining time preference (his 8% discount) - having a tr
58.
by boyband6666 7y ago
This is exactly correct. Also there is a good incentive structure in there - a well designed clinical trial program will move between phases, collect all data possible to support an application, and have all the relevant data to get a timel
59.
by boyband6666 7y ago
Simple answer is probably not; even a lowering of standards you still need to know if it works - so still doing studies. You'd also then get more drugs like Lily's recently that in post-marketing turns out not to work, but ate of
60.
by boyband6666 8y ago
See an example of transport unions in the UK. Tube drivers are in the top 5%/10% of income in the UK, for a 35 hour or so week, and a lot of other benefits. The union power has done amazing things for them... but at a huge cost (albeit

More ›